Business Context and Reporting Period
This Form 8-K Current Report was filed by ADVENTRX Pharmaceuticals, Inc. on April 23, 2010. The filing addresses a corporate action regarding the company's capital structure rather than operational results for a specific fiscal period.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data point disclosed is the valuation used for fractional share payments: $4.6275 per share (post-split basis), representing the closing price on the NYSE Amex on April 23, 2010.
Material Changes
- Reverse Stock Split: The company executed a 1-for-25 reverse split of its common stock, effective at 4:01 p.m. Eastern Daylight Time on April 23, 2010.
- Share Reclassification: Every 25 shares of common stock issued and outstanding prior to the effective time were automatically reclassified into one share of common stock.
- Fractional Shares: No fractional shares were issued. Stockholders entitled to fractional shares received a cash payment calculated by multiplying the fractional interest by $4.6275.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. The document is strictly a notification of the amendment to the Certificate of Incorporation to effect the reverse stock split.
Investor Verification Checklist
- Verify the post-split share count and ownership percentage adjustments in brokerage accounts.
- Confirm receipt of cash payments for any fractional shares, calculated at the $4.6275 rate.
- Review the attached Exhibit 3.1 (Certificate of Amendment) for specific details on the amended charter.
- Note that the company name in the filing is ADVENTRX Pharmaceuticals, Inc., despite the request metadata referencing Savara Inc.